WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP (“RTW”), subject to United States Food and Drug Administration (FDA) approval of Anaphylm™ (epinephrine) Sublingual Film and other conditions.
Related Questions
What is the expected timeline for FDA approval of Anaphylm™ (epinephrine) Sublingual Film?
What are the key regulatory milestones and associated risks for the sublingual film product?
What are the specific terms and valuation of the $75M strategic funding agreement with RT W?
How will the funding affect AQST’s cash runway and future capital needs?
How might the announcement impact AQST’s stock price in the short term?
What dilution or share issuance is anticipated as part of the funding agreement?
How does Anaphylm™’s market potential compare to existing epinephrine delivery products and competitors?
What is the projected revenue and profit contribution of Anaphylm™ once commercialized?
Are there any covenants or performance milestones tied to the RT W funding that could affect future financing?
How will this strategic partnership with RT W influence AQST’s strategic positioning and partnership opportunities in the broader drug delivery space?